VALN - Valneva reports FY results

Valneva press release (NASDAQ:VALN): FY Revenue of €348.1M (+215.6% Y/Y). €253.3M of COVID-related revenues under the terminated U.K. agreement. €94.8M of product and other revenues (excluding COVID), at the higher end of previous guidance of €85M to €100M. Cash and cash equivalents increased to €346.7M as of December 31, 2021, compared to €204.4M as of December 31, 2020. FY 2022 guidance: Total revenues expected between €430M to €590M, including: €350M to €500M of COVID-19 vaccine sales subject to regulatory approvals and deliveries of VLA2001, €60M to €70M of other vaccine sales Approx. €20M of Other Revenues

For further details see:

Valneva reports FY results